Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome

Journal of Clinical Psychiatry

Volumn 71, Issue 8, 2010, Pages 1007-1016

  Zeugmann, Sara ^a   Quante, Arnim ^a   Heuser, Isabella ^a   Schwarzer, Ralf ^b   Anghelescu, Ion ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; INTERLEUKIN 6; RESISTIN; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HOSPITAL ADMINISTRATOR; HOSPITAL PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL ASSESSMENT; METABOLIC SYNDROME X; PRIORITY JOURNAL;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; E-SELECTIN; FEMALE; FIBRINOGEN; HOSPITALIZATION; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952012895     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04767blu     Document Type: Article

References (79)

1. Weber-Hamann B, Kopf D, Lederbogen F, et al. Activity of the hypothalamus-pituitary-adrenal system and oral glucose tolerance in depressed patients. Neuroendocrinology. 2005;81(3):200-204.
2. Jakovljević M, Crncević Z, Ljubicić D, et al. Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub. 2007;19(1-2):76-86.
3. Everson-Rose SA, Meyer PM, Powell LH, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care. 2004;27(12):2856-2862.
4. Capuron L, Su S, Miller AH, et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry. 2008;64(10):896-900.
5. Kylin E. Studien über das Hypertonie-Hyperglykämie- Hyperurikämie-Syndrom. Zentralblatt für Innere Medizin. 1923;44:104-126.
6. Vague J. La difference sexuelle, facteur déterminant des formes de l'obésité. Presse Mèd. 1947;30:339-340.
7. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428.
9. Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry. 2006;67(9):1422-1427.
10. Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry. 2005;66(5):559-563.
11. Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med. 2004;66(3):316-322.
12. Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, et al. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry. 2008;69(2):178-182. PubMed doi:10.408/JCP.v69n0202 (Pubitemid 351469259)
13. Räikkönen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care. 2007;30(4):872-877.
14. Pulkki-Råback L, Elovainio M, Kivimäki M, et al. Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. Health Psychol. 2009;28(1):108-116.
15. Goldbacher EM, Bromberger J, Matthews KA. Lifetime history of major depression predicts the development of the metabolic syndrome in middle-aged women. Psychosom Med. 2009;71(3):266-272.
16. Anisman H, Merali Z. Cytokines, stress, and depressive illness. Brain Behav Immun. 2002;16(5):513-524.
17. Muldoon MF, Mackey RH, Korytkowski MT, et al. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab. 2006;91(2):718-721.
18. McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev. 2005;85(2):571-633.
19. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-47.
20. Kowalska I, Straczkowski M, Nikolajuk A, et al. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism. 2008;57(11):1539-1544.
21. Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25(11):2016-2021.
22. Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003;27(4):443-449.
23. Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2004;2(2):82-104.
24. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796- 1808. PubMed (Pubitemid 38063703)
25. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106(23):2908-2912.
26. Kim YK, Na KS, Shin KH, et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1044-1053.
27. Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs. 2005;65(11):1493-1520.
28. Lespérance F, Frasure-Smith N, Théroux P, et al. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry. 2004;161(2):271-277.
29. Miller GE, Stetler CA, Carney RM, et al. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol. 2002;90(12):1279-1283.
30. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35(4):298-306.
31. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31. PubMed doi:10.1016/j.it.205.1.06 (Pubitemid 43083561)
32. Carney RM, Freedland KE, Miller GE, et al. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53(4):897-902.
33. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. 2001;15(1):7-24.
34. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12(11):988-1000.
35. Vaccarino V, Brennan ML, Miller AH, et al. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry. 2008;64(6):476-483.
36. Lanquillon S, Krieg JC, Bening-Abu-Shach U, et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370-379.
37. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol. 2004;19(6):397-403.
38. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand. 1998;97(4):309-313. PubMed doi:10.1/j.160-047.198.tb105.x (Pubitemid 28179269)
39. Whooley MA, Caska CM, Hendrickson BE, et al. Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol Psychiatry. 2007;62(4):314-320.
40. Leo R, Di Lorenzo G, Tesauro M, et al. Decreased plasma adiponectin concentration in major depression. Neurosci Lett. 2006;407(3):211-213.
41. You T, Nicklas BJ, Ding J, et al. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci. 2008;63(4):414-419.
42. Kling MA, Alesci S, Csako G, et al. Sustained low-grade proinflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry. 2007;62(4):309-313.
43. Liu J, Young TK, Zinman B, et al. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. Obesity (Silver Spring). 2006;14(3):500-508. PubMed doi:10.1038/oby.206.65 (Pubitemid 46219770)
44. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. ATTICA study. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J. 2004;25(6):492-499.
45. Ford ES, Ajani UA, Mokdad AH; National Health and Nutrition Examination. The metabolic syndrome and concentrations of C-reactive protein among US youth. Diabetes Care. 2005;28(4):878-881.
46. Maes M, Bosmans E, De Jongh R, et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9(11):853-858.
47. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86(3):1154-1159.
48. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95(5):2111-2119.
49. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003;88(11):5452-5455.
50. Pan A, Ye X, Franco OH, et al. The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese. PLoS One. 2008;3(1):e1392.
51. Rajagopalan S, Brook R, Rubenfire M, et al. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol. 2001;88(2):196-198, A7. PubMed doi:10.1016/S02-9149(01)01623-X (Pubitemid 32607714)
52. Rowley K, Walker KZ, Cohen J, et al. Inflammation and vascular endothelial activation in an Aboriginal population: relationships to coronary disease risk factors and nutritional markers. Med J Aust. 2003;178(10):495-500.
53. Kressel G, Trunz B, Bub A, et al. Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis. 2009;202(1):263-271.
54. Natal C, Restituto P, Iñigo C, et al. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab. 2008;93(6):2319-2327.
55. Wittchen HU, Wunderlich U, Gruschwitz S, et al. SKID I: Strukturiertes Klinisches Interview für DSM-IV, Achse I: psychische Störungen. Göttingen, Germany: Hogrefe; 1997.
56. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
57. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
58. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237-242.
59. O'Brien SM, Fitzgerald P, Scully P, et al. Impact of gender and menstrual cycle phase on plasma cytokine concentrations. Neuroimmunomodulation. 2007;14(2):84-90.
60. Narita K, Murata T, Takahashi T, et al. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1159-1162. PubMed doi:10.1016/j.pnpbp.206.03.030 (Pubitemid 43928220)
61. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):201-217.
62. Sluzewska A, Rybakowski J, Bosmans E, et al. Indicators of immune activation in major depression. Psychiatry Res. 1996;64(3):161-167.
63. Reilly MP, Rohatgi A, McMahon K, et al. Plasma cytokines, metabolic syndrome, and atherosclerosis in humans. J Investig Med. 2007;55(1):26-35.
64. Hu G, Qiao Q, Tuomilehto J, et al. DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066-1076.
65. Vaccarino V, McClure C, Johnson BD, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med. 2008;70(1):40-48.
66. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42(2):151-157.
67. Brunner J, Bronisch T, Pfister H, et al. High cholesterol, triglycerides, and body-mass index in suicide attempters. Arch Suicide Res. 2006;10(1):1-9. PubMed doi:10.1080/1381050318083 (Pubitemid 43860451)
68. Colin A, Reggers J, Castronovo V, et al. [Lipids, depression and suicide]. (Article in French) Encephale. 2003;29(1):49-58.
69. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.
70. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol. 2005;20(7):473-476.
71. Szuster-Ciesielska A, Tustanowska-Stachura A, Słotwińska M, et al. In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol J Pharmacol. 2003;55(3):353-362.
72. O'Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 2007;41(3-4):326-331.
73. Piletz JE, Halaris A, Iqbal O, et al. Pro-inflammatory biomarkers in depression: treatment with venlafaxine. World J Biol Psychiatry. 2009;10(4):313-323.
74. Eller T, Vasar V, Shlik J, et al. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):445-450.
75. Weber-Hamann B, Kratzsch J, Kopf D, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res. 2007;41(3-4):344-350.
76. Miller GE, Freedland KE, Carney RM, et al. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun. 2003;17(4):276-285.
77. Pitsavos C, Panagiotakos DB, Chrysohoou C, et al. The associations between physical activity, inflammation, and coagulation markers, in people with metabolic syndrome: the ATTICA study. Eur J Cardiovasc Prev Rehabil. 2005;12(2):151-158. PubMed doi:10.1097/0149831-205040-010 (Pubitemid 40575757)
78. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006;91(2):439-446.
79. Blackburn P, Després JP, Lamarche B, et al. Postprandial variations of plasma inflammatory markers in abdominally obese men. Obesity (Silver Spring). 2006;14(10):1747-1754. PubMed doi:10.1038/oby.206.201 (Pubitemid 46214797)